Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to -$1.3 million.

  • Abvc Biopharma's Net Income towards Common Stockholders fell 59013.51% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 20179.78%. This contributed to the annual value of $5.3 million for FY2024, which is 14844.07% up from last year.
  • Abvc Biopharma's Net Income towards Common Stockholders amounted to -$1.3 million in Q3 2025, which was down 59013.51% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Net Income towards Common Stockholders ranged from a high of $10.4 million in Q4 2024 and a low of -$7.9 million during Q4 2021
  • Over the past 5 years, Abvc Biopharma's median Net Income towards Common Stockholders value was -$2.0 million (recorded in 2021), while the average stood at -$1.9 million.
  • As far as peak fluctuations go, Abvc Biopharma's Net Income towards Common Stockholders skyrocketed by 40102.6% in 2024, and later plummeted by 59013.51% in 2025.
  • Over the past 5 years, Abvc Biopharma's Net Income towards Common Stockholders (Quarter) stood at -$7.9 million in 2021, then soared by 38.68% to -$4.9 million in 2022, then grew by 29.03% to -$3.5 million in 2023, then skyrocketed by 401.03% to $10.4 million in 2024, then tumbled by 112.39% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$2.3 million for Q2 2025, and $944190.0 during Q1 2025.